Dear Valued Visitor,

We have noticed that you are using an ad blocker software.

Although advertisements on the web pages may degrade your experience, our business certainly depends on them and we can only keep providing you high-quality research based articles as long as we can display ads on our pages.

To view this article, you can disable your ad blocker and refresh this page or simply login.

We only allow registered users to use ad blockers. You can sign up for free by clicking here or you can login if you are already a member.

Is Teva Pharmaceutical Industries Ltd (TEVA) Planning Celltrion Takeover To Bolster Biosimilar Portfolio?

Reports in the pharmaceutical space indicate that Teva Pharmaceutical Industries Ltd (NYSE:TEVA) might be planning to acquire South Korea biosimilar giant Celltrion. Talk of a possible takeover comes just days after the generic giant completed the acquisition of Canadian and US rights for the company’s two biosimilars. The two drugs in question are copies of Roche Holding Ltd.’s Rituxan and Herceptin.

Consolidation Wave

Teva is aggressively looking for ways to bolster its portfolio of drugs with biosimilars having only struck one deal on this front to date. Since wrapping up the $40 billion takeover of Allergan generics business, the Israeli-based company has been aggressive in diversifying its portfolio of drugs with branded drug assets among other specialty assets.

A takeover of Celltrion by Teva would not come as a surprise given the wave of consolidation in the pharmaceutical space. Companies in the sector have sought to bolster their portfolio of drugs in the recent past by acquiring smaller companies with drugs in areas of immense growth opportunities such as oncology.

pharmacist, medical, retail, worker, team, young, staff, lab, chemistry, business, drug, chemist, adult, teamwork, drugstore, service,


Teva Big Play

By acquiring Celltrion, Teva would be able to gain access to the company’s vast portfolio of biosimilars some of which have already gained regulatory approval. The company already boasts of an FDA-approved biosimilar to Johnson & Johnson (NYSE:JNJ)’s Remicade.

Fuelling speculation of a possible takeover is the fact that the company’s spokesperson has confirmed they are looking for new opportunities in South Korea.

“We will continue to investigate such opportunities as we balance risk and seek complementary skills in our partners,” he said.

This is not the first time that Teva has been linked to a takeover of the Korean company. In 2014, its name popped in addition to AstraZeneca Plc (NYSE:AZN) and Roche as a potential acquirer of a controlling stake in the company. The South Korean company, later on, scrapped plans to sell off a controlling stake after making progress on its biosimilar candidate Remsima, consequently forging a partnership with Pfizer for its sale.

Follow Teva Pharmaceutical Inds Ltd (NYSE:TEVA)
Trade (NYSE:TEVA) Now!

Teva stock was a big disappointment in Monday’s trading session, having shed 2.72% in market value to open the week on a low of $41.79 a share, but rebounded to gain 3.49% in Tuesday’s session.

Note: This article is written by Adam Russell and was originally published at Market Exclusive.

Biotech Stock Alert - 20% Guaranteed Return in One Year

Hedge Funds and Insiders Are Piling Into

One of 2015's best hedge funds and two insiders snapped up shares of this medical device stock recently. We believe its transformative and disruptive device will storm the $3+ billion market and help it achieve 500%-1000% gains in 3 years.

Get your FREE REPORT and the details of our 20% return guarantee today.

Subscribe me to Insider Monkey's Free Daily Newsletter
This is a FREE report from Insider Monkey. Credit Card is NOT required.
Loading Comments...

Thanks! An email with instructions is sent to !

Your email already exists in our database. Click here to go to your subscriptions

Insider Monkey returned 102% in 3 years!! Wondering How?

Download a complete edition of our newsletter for free!